目的 观察伏格列波糖联合利拉鲁肽治疗2型糖尿病的临床疗效。方法 选取无棣县人民医院2015年10月-2016年9月接诊的2型糖尿病患者106例，随机分为对照组和治疗组，每组各53例。对照组皮下注射利拉鲁肽注射液，起始剂量为0.6 mg/d，1周后增至1.2 mg/d，1次/d；治疗组在对照组的基础上口服伏格列波糖片，0.2 mg/次，3次/d。两组患者均治疗12周。比较治疗前后两组患者临床疗效、血糖和血脂指标水平改善情况。结果 治疗后，对照组临床总有效率为81.13%，显著低于治疗组的94.34%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者空腹血糖（FPG）、早餐后2 h血糖（2 h PG）和糖化血红蛋白等血糖指标，以及三酰甘油（TG）、胆固醇（CHO）和低密度脂蛋白（LDL-C）等血脂指标水平均显著下降，同组比较差异具有统计学意义（P<0.05）；且治疗组患者血糖、血脂指标明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 伏格列波糖联合利拉鲁肽治疗2型糖尿病临床疗效显著，可明显改善化验指标，且不良反应较少，具有一定的临床推广应用价值。

Objective To observe the clinical curative effect of voglibose combined with liraglutide in treatment of type 2 diabetes. Methods Patients (106 cases) with type 2 diabetes in Wudi People's Hospital from October 2015 to September 2016 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were subcutaneous injection administered with Liraglutide Injection, the initial dosage was 0.6 mg/d, and increased to 1.2 mg/d after one week, once daily. Patients in the treatment group were po administered with Voglibose Tablets on the basis of the control group, 0.2 mg/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, clinical efficacy, and the improvement of blood glucose and serum lipid levels in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 81.13%, which was significantly lower than 94.34% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the fasting blood glucose, 2 h blood sugar after breakfast and glycosylated hemoglobin of the blood glucose indexes, and the serum lipid levels of TG, CHO and LDL-C in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of blood glucose and serum lipid in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Voglibose combined with liraglutide has satisfactory clinical efficacy in treatment of type 2 diabetes, can significantly improve laboratory indexes with less adverse reactions, which has a certain clinical application value.